Topic - Biogen

Biogen, Inc. (previously known as Biogen Idec) is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases to patients worldwide. - Source: Wikipedia

Related Stories

Illustration on domestic drug manufacturing by Alexander Hunter/The Washington Times

Securing medicine manufacturing is key to the ‘America First’ agenda

By Jamey Bowers

Drug for rare form of Lou Gehrig’s disease OK’d by FDA

By Matthew Perrone - Associated Press

This Dec. 21, 2022 image provided by Eisai in January 2023, shows vials and packaging for their medication Leqembi. On Friday, Jan. 6, 2023, U.S. health officials approved Leqembi, a new Alzheimer’s drug that modestly slows the brain-robbing disease. The Food and Drug Administration granted the approval Friday for patients in the early stages of Alzheimer's. (Eisai via AP)

U.S. approves Alzheimer’s drug that modestly slows disease

By Matthew Perrone - Associated Press

This illustration made available by the National Institute on Aging/National Institutes of Health depicts cells in an Alzheimer’s affected brain, with abnormal levels of the beta-amyloid protein clumping together to form plaques, brown, that collect between neurons and disrupt cell function. Abnormal collections of the tau protein accumulate and form tangles, blue, within neurons, harming synaptic communication between nerve cells. An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers reported Tuesday, Nov. 29, 2022 — and the next question is how much difference that might make in people’s lives. Japanese drugmaker Eisai and its U.S. partner Biogen had announced earlier this fall that the drug lecanemab appeared to work, a badly needed bright spot after repeated disappointments in the quest for better Alzheimer’s treatments. (National Institute on Aging, NIH via AP)

Drug slows Alzheimer’s, but can it make a real difference?

By Lauran Neergaard - Associated Press

This 2018 photo provided by Amylyx shows the company's co-founders Joshua Cohen, left, and Justin Klee in Cambridge, Mass. on Sept. 2, 2022. A closely watched experimental drug for Lou Gehrig’s disease is getting an unusual second look from U.S. regulators on Wednesday, Sept. 7, 2022, amid intense pressure to approve the treatment for patients with the fatal illness. Patients and their families have rallied behind the drug from Amylyx Pharma, launching an aggressive lobbying campaign and enlisting members of Congress to push the Food and Drug Administration to grant approval. (Amylyx via AP, File)

FDA panel backs much-debated ALS drug in rare, 2nd review

By Matthew Perrone - Associated Press

FILE - Sen. Bernie Sanders, I-Vt., speaks during a news conference on Capitol Hill, Nov. 3, 2021, in Washington. Sanders is asking the White House to cut back a big Medicare premium hike set to take effect in weeks and tied to a pricey Alzheimer’s drug whose benefits have been widely questioned. (AP Photo/Alex Brandon, File)

Sanders to Biden: Cut back looming Medicare premium hike

By Ricardo Alonso-Zaldivar - Associated Press

Dementia Drug Problems for Black and Hispanic Communities Illustration by Greg Groesch/The Washington Times

Targeting Black and Hispanic communities for dementia drugs

By Naisa Rahman and Caroline Renko

FILE - This image provided by Biogen on Monday, June 7, 2021 shows a vial and packaging for the drug Aduhelm. The first new Alzheimer’s treatment in more than 20 years was hailed as a breakthrough when regulators approved it in June 2021, but its rollout has been slowed by questions about its price and how well it works. (Biogen via AP, File)

In quiet debut, Alzheimer’s drug finds questions, skepticism

By Tom Murphy - Associated Press

FILE - This image provided by Biogen on Monday, June 7, 2021 shows a vial and packaging for the drug Aduhelm. On Friday, July 9, 2021, the acting head of the U.S. Food and Drug Administration called for a government investigation into highly unusual contacts between some of her agency's drug reviewers and the maker of the controversial new Alzheimer's drug. (Biogen via AP, File)

FDA head calls for inquiry into Alzheimer’s drug review

By Matthew Perrone - Associated Press

In this 2019 photo provided by Biogen, a researcher works on the development of the medication aducanumab in Cambridge, Mass. On Monday, June 7, 2021, the Food and Drug Administration approved aducanumab, the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease. (Biogen via AP)

FDA approves much-debated Alzheimer’s drug panned by experts

By Matthew Perrone - Associated Press

Biogen agrees to pay $22M to settle kickback allegations

Associated Press

15 more in Massachusetts test positive for coronavirus

Associated Press

Markets Right Now: Stocks end mostly lower on Wall Street

Associated Press

FILE- In this March 12, 2019, file photo a handheld device of trader Sal Suarino is reflected in his glasses as he works on the floor of the New York Stock Exchange. The U.S. stock market opens at 9:30 a.m. EDT on Thursday, March 21. (AP Photo/Richard Drew, File)

Markets Right Now: Tech leads US stocks broadly higher

Associated Press